Exporting the Reference Price: How US Most-Favoured-Nation Drug Pricing Turned Switzerland into America’s Price Anchor
Once prices are adjusted for income, Switzerland has the lowest drug prices in the US most-favoured-nation basket and sets the US price for about 83 percent of new medicines. That explains why a third of new medicines are being withheld from Swiss reimbursement, and what a targeted launch-price uplift would cost premium payers.
The Pharma Mirage: Measuring Swiss Growth When One Industry Writes the Headlines
Chemicals and pharmaceuticals are 7 percent of Swiss GDP but now drive 37 percent of the variance of quarterly growth. Stripping the industry out shows there was no recession in 2025, that real output per head outside pharma grew only 0.3 percent a year over a decade, and that the 2026 recovery rests on foreign rather than domestic demand.
Tariff Whiplash: What Five US Tariff Regimes Reveal About the Swiss Export Model
Between April 2025 and August 2026 Swiss goods faced five different US tariff regimes, from 10 to 39 per cent and back. Using three validated counterfactuals, this paper shows that the tariff rate explains almost none of the export loss. A steady, tariff-insensitive drift does: the signature of production relocating to the United States.